Geno J. Germano Acquires 3,605 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano acquired 3,605 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average cost of $4.49 per share, with a total value of $16,186.45. Following the acquisition, the director now directly owns 7,807 shares of the company’s stock, valued at $35,053.43. This trade represents a 85.79 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.

Precision BioSciences Trading Up 23.1 %

Shares of Precision BioSciences stock opened at $4.69 on Friday. The company’s fifty day simple moving average is $6.52 and its 200-day simple moving average is $8.48. Precision BioSciences, Inc. has a 1-year low of $3.61 and a 1-year high of $19.43. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The stock has a market capitalization of $35.98 million, a PE ratio of 78.18 and a beta of 1.41.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Precision BioSciences stock. Janus Henderson Group PLC raised its position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 702,069 shares of the company’s stock after purchasing an additional 68,943 shares during the quarter. Janus Henderson Group PLC owned 9.15% of Precision BioSciences worth $6,322,000 as of its most recent SEC filing. 37.99% of the stock is currently owned by institutional investors.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.